Cardiovascular effects of resveratrol and atorvastatin treatments in an H2O2‑induced stress model

Soner,Burak Cem; Şahin,Ayşe Saide

doi:10.3892/etm.2014.1956

Cardiovascular effects of resveratrol and atorvastatin treatments in an H2O2‑induced stress model

Authors:
- Burak Cem Soner
- Ayşe Saide Şahin
View Affiliations

Affiliations: Department of Medical Pharmacology, Meram Medical Faculty, Necmettin Erbakan University, Konya 42080, Turkey
Published online on: September 11, 2014 https://doi.org/10.3892/etm.2014.1956
Pages: 1660-1664

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxidative stress has been implicated in the pathophysiology of several types of cardiovascular disease (CVD). Statins are widely used to inhibit the progression of atherosclerosis and reduce the incidence of CVD. Certain over‑the‑counter products, including resveratrol, show similar effects to statins and may thus be used in conjunction with statins for the treatment of the majority of patients with CVD. The aim of the present study was to evaluate the effects of atorvastatin, resveratrol and resveratrol + atorvastatin (R+A) pretreatment on myocardial contractions and vascular endothelial functions in the presence of H2O2 as an experimental model of oxidative stress in rats. Four groups were established and referred to as the control, atorvastatin, resveratrol and R+A groups. Atorvastatin (40 mg/kg, per oral) and/or resveratrol (30 mg/kg, intraperitoneal) treatments were administered for 14 days. On the 15th day, the thoracic aortas and hearts of the rats were dissected and placed into isolated organ baths. Vascular responses to cumulative doses of H2O2 (1x10‑8‑1x10‑4 M H2O2) with and without N (G)‑nitro‑L‑arginine methyl ester (L‑NAME) incubation were measured. In addition, myocardial electrical stimulation (ES) responses to various H2O2 concentrations (1x10‑7‑1x10‑5 M H2O2) were evaluated. In the control and atorvastatin groups, H2O2 application caused a significant dose‑dependent decrease in the ES‑induced contractions in the myocardial tissue of rats. In the resveratrol and R+A groups, H2O2 application did not significantly affect myocardial contraction at any dose. In all groups, incubation with L‑NAME caused a significant augmentation in the H2O2 response, revealing that this effect was mediated via the vascular endothelium. In conclusion, pretreatment with R+A for CVD appears to be superior to pretreatment with either agent alone.

View Figures

View References

1	Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF Jr and Loscalzo J: Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med. 41:1455–1461. 2003. View Article : Google Scholar : PubMed/NCBI
2	Landmesser U, Spiekermann S, Dikalov S, et al: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 106:3073–3078. 2002. View Article : Google Scholar
3	Forgione MA, Leopold JA and Loscalzo J: Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol. 15:409–415. 2000. View Article : Google Scholar : PubMed/NCBI
4	Eyries M, Collins T and Khachigian LM: Modulation of growth factor gene expression in vascular cells by oxidative stress. Endothelium. 11:133–139. 2004. View Article : Google Scholar : PubMed/NCBI
5	Harrison D, Griendling KK, Landmesser U, Hornig B and Drexler H: Role of oxidative stress in atherosclerosis. Am J Cardiol. 91:7A–11A. 2003. View Article : Google Scholar : PubMed/NCBI
6	Prasad K and Lee P: Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther. 8:61–69. 2003. View Article : Google Scholar : PubMed/NCBI
7	Vassalle C, Petrozzi L, Botto N, Andreassi MG and Zucchelli GC: Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med. 256:308–315. 2004. View Article : Google Scholar : PubMed/NCBI
8	Futterman LG and Lemberg L: Statin pleiotropy: fact or fiction? Am J Crit Care. 13:244–249. 2004.PubMed/NCBI
9	Bell RM and Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 41:508–515. 2003. View Article : Google Scholar : PubMed/NCBI
10	Soner BC, Murat N, Demir O, Guven H, Esen A and Gidener S: Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction? Int J Impot Res. 22:227–233. 2010. View Article : Google Scholar : PubMed/NCBI
11	Sinzinger H, Chehne F and Lupattelli G: Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf. 25:877–883. 2002. View Article : Google Scholar : PubMed/NCBI
12	Parker RA, Huang Q and Tesfamariam B: Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis. 169:19–29. 2003. View Article : Google Scholar : PubMed/NCBI
13	Satoh K, Yamato A, Nakai T, Hoshi K and Ichihara K: Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol. l16:1894–1898. 1995. View Article : Google Scholar
14	Ichihara K, Satoh K, Yamamoto A and Hoshi K: Are all HMG-CoA reductase inhibitors protective against ischemic heart disease? Nippon Yakurigaku Zasshi. 114(Suppl 1): 142P–l49P. 1999.(In Japanese).
15	März W, Siekmeier R, Müller HM, Wieland H, Gross W and Olbrich HG: Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharrnacol Ther. 5:275–279. 2000.PubMed/NCBI
16	Pisarenko OI, Studneva IM, Lankin VZ, et al: Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats. Bull Exp Biol Med. 132:956–958. 2001. View Article : Google Scholar : PubMed/NCBI
17	Sahin AS, Görmüş N and Duman A: Preconditioning with levosimendan prevents contractile dysfunction due to H₂O₂-induced oxidative stress in human myocardium. J Cardiovasc Pharmacol. 50:419–423. 2007. View Article : Google Scholar : PubMed/NCBI
18	McQuaid KE, Smyth EM and Keenan AK: Evidence for modulation of hydrogen peroxide-induced endothelial barrier dysfunction by nitric oxide in vitro. Eur J Pharmacol. 307:233–241. 1996. View Article : Google Scholar : PubMed/NCBI
19	Barlow RS, El-Mowafy AM and White RE: H(2)O(2) opens BK(Ca) channels via the PLA(2)-arachidonic acid signaling cascade in coronary artery smooth muscle. Am J Physiol Heart Circ Physiol. 279:H475–H483. 2000.PubMed/NCBI
20	Lacy F, O’Connor DT and Schmid-Schönbein GW: Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 16:291–303. 1998. View Article : Google Scholar : PubMed/NCBI
21	Halliwell B, Clement MV and Long LH: Hydrogen peroxide in the human body. FEBS Lett. 486:10–13. 2000. View Article : Google Scholar : PubMed/NCBI
22	Lankin VZ, Tikhaze AK, Kaminnaia VI, Kaminnyĭ AI, Konovalova GG and Kukharchuk VV: Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10. Biull Eksp Biol Med. 129:176–179. 2000.(In Russian).
23	Lankin VZ, Tikhaze AK, Kukharchuk VV, et al: Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem. 249:129–140. 2003. View Article : Google Scholar : PubMed/NCBI
24	Lankin VZ and Tikhaze AK: Atherosclerosis as a free radical pathology and antioxidative therapy of this disease. Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical, and Clinical Aspects. Tomasi A, Özben T and Skulachev VP: (NATO Science Series). 344. IOS Press; Amsterdam: pp. 218–231. 2003
25	Robicsek F and Schaper J: Reperfusion injury: fact or myth? J Card Surg. 12:133–137. 1997. View Article : Google Scholar : PubMed/NCBI
26	Thomas MK, Narang D, Lakshmy R, Gupta R, Naik N and Maulik SK: Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients ‘on’ and ‘off’ atorvastatin for short time intervals. Cardiovasc Drugs Ther. 20:37–44. 2006.PubMed/NCBI
27	Wassmann S, Ribaudo N, Faul A, Laufs U, Böhm M and Nickenig G: Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. Am J Cardiol. 93:84–88. 2004. View Article : Google Scholar : PubMed/NCBI
28	Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R and Dohi Y: Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 20:133–136. 2005. View Article : Google Scholar : PubMed/NCBI
29	Marketou ME, Zacharis EA, Nikitovic D, et al: Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology. 57:211–218. 2006. View Article : Google Scholar : PubMed/NCBI
30	Argüelles S, Garcia S, Maldonado M, Machado A and Ayala A: Do the serum oxidative stress biomarkers provide a reasonable index of the general oxidative stress status? Biochim Biophys Acta. 1674:251–259. 2004.PubMed/NCBI
31	Hargreaves IP, Duncan AJ, Heales SJ and Land JM: The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf. 28:659–676. 2005. View Article : Google Scholar : PubMed/NCBI
32	Li YG, Zhu W, Tao JP, et al: Resveratrol protects cardiomyocytes from oxidative stress through SIRT1 and mitochondrial biogenesis signaling pathways. Biochem Biophys Res Commun. 438:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
33	Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI